main content start
Steglujan (ertugliflozin and sitagliptin) is a combination medication containing an SGLT-2 inhibitor class of drugs (ertugliflozin) and DPP-4 inhibitor (sitagliptin). Steglujan blocks glucose from being reabsorbed by the kidneys. Excess glucose is released in the urine. Some medications in the SGLT-2 inhibitor class may offer heart and kidney benefits for people with cardiovascular disease.
It is approved for adults with type 2 diabetes.
- Steglujan helps the kidneys get rid of glucose from the bloodstream and regulates the body's insulin production after eating in adults with type 2 diabetes.
- It is not for treating type 1 diabetes.
- Medications like Steglujan may offer heart and kidney benefits for people with cardiovascular disease.
- Steglujan usually has an initial dose of one tablet (ertugliflozin 5 mg/sitagliptin 100 mg) taken by mouth once daily in the morning with or without food.
- If needed and tolerated, it may be increased to a maximum dose of ertugliflozin 15 mg/sitagliptin 100 mg.
- Common side effects may include urinating more than usual, genital-urinary infection, upset stomach, diarrhea, headache, or cold-like symptoms.
Steglujan Specs
Key specification
Generic Name
Ertugliflozin and Sitagliptin
Drug Class
SGLT-2 inhibitors
General Information
Product Name
Steglujan
Product Type
Oral Medications
Brand
Merck
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
